J&J multiple myeloma drugs Tecvayli and Talvey boost cancer-free survival in late-stage trial

Johnson & Johnson's multiple myeloma drugs, Tecvayli and Talvey, have shown promising results in late-stage trials, significantly boosting cancer-free survival rates for patients.